admin – Page 3724 – Get News Story

3rd Degree Screening Enhances Background Check Offerings with Smart Screen™, Powered By Equifax®

3rd Degree Screening has partnered with Equifax® to enhance its background check solutions by offering Smart Screen™.

Smart Screen Helps Streamline Criminal Background Checks for Faster, More Efficient Hiring Decisions

3rd Degree Screening, Inc., a leading provider of comprehensive background check solutions, now offers Smart Screen™, a suite of advanced criminal screening solutions by Equifax®. This collaboration empowers employers with a new first step in their background screening workflow that can enable greater efficiency for faster criminal background checks and well-informed hiring decisions.

“In today’s competitive hiring environment, speed and efficiency are essential for effective background screening,” said Jimmy Waters, CEO at 3rd Degree Screening. “The innovative approach to criminal record checks that Smart Screen offers, including leveraging a vast proprietary incarceration data network, allows us to quickly complete screenings for many candidates, enabling faster onboarding for our customers. This aligns perfectly with our commitment to providing clients with the most reliable and efficient screening tools available.”

Smart Screen checks for an absence of records in a vast U.S. incarceration data network and an extensive sex offender registry network to deliver instant consumer reports when available, enabling quicker hiring decisions. The expansive incarceration data network covers approximately 185 million records from more than 1,900 county jails and 30 state prison systems, with data updated as frequently as every 15 minutes. When a report is able to be generated it must be used for permissible purposes as defined by the Fair Credit Reporting Act (FCRA). “We are excited to partner with 3rd Degree Screening to bring the power of Smart Screen to their clients,” said Bart Lautenbach, Senior Vice President and General Manager -Talent Solutions at Equifax. “This collaboration will provide employers with the tools they need to help make informed hiring decisions more quickly and efficiently.”

“Smart Screen™ is not just another database search — it’s an industry-changing solution. We have extensively tested its capabilities and are confident that it offers an unprecedented level of accuracy, coverage, and speed. Unlike conventional systems that rely solely on name-matching, Smart Screen leverages Personally Identifiable Information (PII) with unmatched criminal coverage. This is a game-changer for the background screening industry and employers. Years from now, we will look back and recognize Smart Screen as a pivotal innovation that reshaped the industry — and we’re proud to be at the forefront of this transformation,” said Jimmy Waters, CEO at 3rd Degree Screening.

More information about Smart Screen is available here.

About 3rd Degree Screening:

3rd Degree Screening is a PBSA-accredited background screening provider committed to delivering fast, reliable, and compliant solutions for businesses across various industries. With a strong focus on accuracy, efficiency, and innovation, we leverage cutting-edge technology and strategic partnerships to help employers make well-informed hiring decisions. By continuously enhancing our offerings, we remain at the forefront of the background screening industry, providing employers with the tools they need to streamline hiring, improve turnaround times, and maintain compliance with regulatory standards.

Media Contact
Company Name: 3rd Degree Screening, Inc
Contact Person: Jimmy Waters
Email: Send Email
Phone: 712-256-5701
Address:100 East Broadway Suite 201
City: Council Bluffs
State: IA
Country: United States
Website: WWW.3RDDEGREESCREENING.COM

Post-Surgical Pain Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Taiwan Liposome Company, Teikoku Pharma USA, Durect, Pfizer, Vivozon, Salvat Laboratories, Vertex Pharma

The Key Post-Surgical Pain Companies in the market include – Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others.

DelveInsight’s “Post-Surgical Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Post-Surgical Pain, historical and forecasted epidemiology as well as the Post-Surgical Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Post-Surgical Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post-Surgical Pain Market Forecast

Some of the key facts of the Post-Surgical Pain Market Report:

The Post-Surgical Pain market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In February 2025, Allay Therapeutics, a clinical-stage biotechnology company focused on ultra-sustained analgesic solutions for post-surgical pain management, has announced the dosing of the first patient in its Phase 2b registration trial evaluating ATX101 for post-surgical pain relief following total knee replacement (TKA) surgery. ATX101, a novel investigational analgesic, aims to deliver long-lasting pain relief, minimizing opioid dependence and enhancing patient recovery.
In January 2024, Taiwan-based Xgene Pharmaceutical reported positive results from its Phase IIb study evaluating XG005, a non-opioid analgesic, for post-surgical acute pain relief. The placebo-controlled, dose-ranging trial (NCT06017999) assessed pain reduction using the summed pain index (SPI) over 48 hours following bunionectomy surgery. The study compared two doses of XG005 (1,250 mg and 750 mg) against a placebo to determine its efficacy.
In November 2024, Averitas Pharma, the U.S. subsidiary of Grünenthal, has successfully completed patient enrollment for its Phase III AV001 clinical trial, evaluating QUTENZA (capsaicin) 8% topical system for the treatment of post-surgical neuropathic pain (PSNP).
Several leading Post-Surgical Pain companies are advancing their key drug candidates through various stages of clinical development, including IV Tramadol by Avenue Therapeutics, Opiranserin (VVZ-149) Injections by Vivozon, OCS-01 by Oculis, among others.
In 2023, the 7MM recorded approximately 67 million incident cases of Post-Surgical Pain. This number is projected to rise by 2032, driven by an increase in traffic accidents, trauma-related injuries, and the growing demand for pain management after surgeries.
In 2023, the US accounted for the highest proportion of incident Post-Surgical Pain cases, contributing approximately 60.41% of the total cases in the 7MM. Meanwhile, EU4 and the UK represented around 21.14%, while Japan accounted for approximately 18.43% of the total cases.
As per DelveInsight, in 2023, the estimated severity-specific incident cases of Post-Surgical Pain in France were approximately 1.2 million mild cases, 1.5 million moderate cases, and 0.8 million severe cases. These numbers are projected to rise by 2032 due to an increasing incidence of Post-Surgical Pain.
In 2023, the estimated severity-specific incident cases of Post-Surgical Pain in Germany were approximately 1.4 million mild cases, 1.7 million moderate cases, and 1 million severe cases. These figures are projected to rise throughout the forecast period (2023–2032).
In the UK, around 4,050,000 new cases of Post-Surgical Pain were reported in 2023.
Key Post-Surgical Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
Key Post-Surgical Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
The Post-Surgical Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post-Surgical Pain pipeline products will significantly revolutionize the Post-Surgical Pain market dynamics.

Post-Surgical Pain Overview

Post-Surgical Pain is discomfort or pain experienced after a surgical procedure due to tissue trauma, nerve damage, or inflammation. It can be acute (short-term) or chronic (lasting beyond the normal healing period, usually over three months).

Pain levels vary based on the type of surgery, individual pain tolerance, and pre-existing conditions. Management includes medications (opioids, NSAIDs, local anesthetics), physical therapy, and nerve blocks to enhance recovery and prevent complications. Proper pain control is crucial to improving patient outcomes and reducing the risk of chronic pain development.

Get a Free sample for the Post-Surgical Pain Market Report:

https://www.delveinsight.com/report-store/post-surgical-pain-market

Post-Surgical Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Post-Surgical Pain Epidemiology Segmentation:

The Post-Surgical Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Number of Incident Cases of Post-Surgical Pain in the 7MM
Total Number of Surgical Procedures(inpatient and outpatient) in the 7MM
Severity-specific Incident Cases of Post-Surgical Pain in the 7MM

Download the report to understand which factors are driving Post-Surgical Pain epidemiology trends @ Post-Surgical Pain Epidemiology Forecast

Post-Surgical Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-Surgical Pain market or expected to get launched during the study period. The analysis covers Post-Surgical Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Post-Surgical Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post-Surgical Pain Therapies and Key Companies

DEXTENZA (dexamethasone): Ocular Therapeutix
ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
IV Tramadol: Avenue Therapeutics
TLC590: Taiwan Liposome Company (TLC)
TPU-006: Teikoku Pharma USA
CA-008: Concentric Analgesics
SVT-15473: Salvat Laboratories
VX-548: Vertex Pharmaceuticals
OCS-01: Oculis
N1539: Baudax Bio
SHR0410: Jiangsu HengRui Medicine
Ketorolac tromethamine: Darnitsa Pharma
AYX1: Adynxx, Inc.
EXPAREL: Pacira Pharma
Toragesic®: Apsen Farmaceutica S.A.
SABER-Bupivacaine: Durect
lyrica: Pfizer
VVZ-149: Vivozon, Inc.
Tapentadol (OS): Grünenthal GmbH
Percocet: Mallinckrodt
YM177: Astellas Pharma Inc
LMX4: Ferndale Laboratories, Inc.

Discover more about therapies set to grab major Post-Surgical Pain market share @ Post-Surgical Pain Treatment Market

Post-Surgical Pain Market Strengths

Drugs with a novel mechanism of action would provide new treatment options to the patients. For instance, SVT-15473 is a “superpotent” corticosteroid that has never been used before as eye drops.
Upcoming therapies are majorly non-opioids which are as effective, and this would reduce opioid dependence and other safety concerns associated with the current opioid medications.

Post-Surgical Pain Market Opportunities

Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market.
Multimodal treatments can be prescribed to reduce the dependency on single-modal treatment. Launching such products will increase the potential ability to treat Post-Surgical Pain.

Scope of the Post-Surgical Pain Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Post-Surgical Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
Key Post-Surgical Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
Post-Surgical Pain Therapeutic Assessment: Post-Surgical Pain current marketed and Post-Surgical Pain emerging therapies
Post-Surgical Pain Market Dynamics: Post-Surgical Pain market drivers and Post-Surgical Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Post-Surgical Pain Unmet Needs, KOL’s views, Analyst’s views, Post-Surgical Pain Market Access and Reimbursement

To know more about Post-Surgical Pain companies working in the treatment market, visit @ Post-Surgical Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Post-Surgical Pain Market Report Introduction

2. Executive Summary for Post-Surgical Pain

3. SWOT analysis of Post-Surgical Pain

4. Post-Surgical Pain Patient Share (%) Overview at a Glance

5. Post-Surgical Pain Market Overview at a Glance

6. Post-Surgical Pain Disease Background and Overview

7. Post-Surgical Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Post-Surgical Pain

9. Post-Surgical Pain Current Treatment and Medical Practices

10. Post-Surgical Pain Unmet Needs

11. Post-Surgical Pain Emerging Therapies

12. Post-Surgical Pain Market Outlook

13. Country-Wise Post-Surgical Pain Market Analysis (2019–2032)

14. Post-Surgical Pain Market Access and Reimbursement of Therapies

15. Post-Surgical Pain Market Drivers

16. Post-Surgical Pain Market Barriers

17. Post-Surgical Pain Appendix

18. Post-Surgical Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Post-Surgical Pain Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Taiwan Liposome Company, Teikoku Pharma USA, Durect, Pfizer, Vivozon, Salvat Laboratories, Vertex Pharma

Cluster Headaches Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer, Sun Pharma, Teva Pharma

The Key Cluster Headaches Companies in the market include – Lundbeck Seattle BioPharmaceutical, Ceruvia Lifesciences, Zosano Pharma Corporation, Biohit Oyj, CCH Pharmaceuticals, Eli Lilly and Company, Winston Laboratories, and others.

The Cluster Headaches market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cluster Headaches pipeline products will significantly revolutionize the Cluster Headaches market dynamics.

DelveInsight’s “Cluster Headaches Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cluster Headaches, historical and forecasted epidemiology as well as the Cluster Headaches market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Cluster Headaches market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Cluster Headaches market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cluster Headaches Market Forecast

Some of the key facts of the Cluster Headaches Market Report:

The Cluster Headaches market size was valued ~USD 890 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the United States held the largest market share for Cluster Headaches among the 7MM, valued at approximately USD 467 million.
As per DelveInsight’s estimates, the United States had the highest number of diagnosed prevalent cases of Cluster Headache among the 7MM in 2023, totaling around 203,000 cases, highlighting its leading position in the market.
Among the EU4 and the UK, Germany recorded the highest number of prevalent Cluster Headache cases in 2023, reaching 98,000 cases, while Spain had the lowest prevalence, with 62,000 cases.
DelveInsight’s estimates indicate that cluster headache cases in the US were classified into episodic and chronic types. In 2023, the episodic form was more prevalent, with approximately 162,000 cases, while the chronic type accounted for around 41,000 cases.
In Germany, gender-specific data for Cluster Headaches in 2023 showed that approximately 41,000 males and 17,700 females were affected.
Key Cluster Headaches Companies: Lundbeck Seattle BioPharmaceutical, Ceruvia Lifesciences, Zosano Pharma Corporation, Biohit Oyj, CCH Pharmaceuticals, Eli Lilly and Company, Winston Laboratories, and others
Key Cluster Headaches Therapies: EMGALITY (Galcanezumab-gnlm), Eptinezumab, NYPRG-101 (BOL-148), C213 Microneedle System, Acetium, Ketamine, Galcanezumab, Civamide (Zucapsaicin), and others
The Cluster Headaches epidemiology based on gender analyzed that Cluster Headaches is more prominent in males in comparison to females

Cluster Headaches Overview

Cluster headaches are a severe type of headache characterized by intense, piercing pain, usually around one eye or on one side of the head. They occur in clusters or groups, meaning that the person experiences multiple headache attacks within a period (a cluster period), which can last weeks or even months. After this period, the headaches may disappear for months or years before recurring.

Get a Free sample for the Cluster Headaches Market Report:

https://www.delveinsight.com/report-store/cluster-headache-market

Cluster Headaches Market

The dynamics of the Cluster Headaches market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Cluster Headaches Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cluster Headaches Epidemiology Segmentation:

The Cluster Headaches market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Cluster Headaches
Prevalent Cases of Cluster Headaches by severity
Gender-specific Prevalence of Cluster Headaches
Diagnosed Cases of Episodic and Chronic Cluster Headaches

Download the report to understand which factors are driving Cluster Headaches epidemiology trends @ Cluster Headaches Epidemiological Insights

Cluster Headaches Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cluster Headaches market or expected to get launched during the study period. The analysis covers Cluster Headaches market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Cluster Headaches Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Cluster Headaches treatment, visit @ Cluster Headaches Medications

Cluster Headaches Therapies and Key Companies

EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company
Eptinezumab: Lundbeck Seattle BioPharmaceutical
NYPRG-101 (BOL-148): Ceruvia Lifesciences
C213 Microneedle System: Zosano Pharma Corporation
Acetium: Biohit Oyj
Ketamine: CCH Pharmaceuticals
Galcanezumab: Eli Lilly and Company
Civamide (Zucapsaicin): Winston Laboratories

Cluster Headaches Market Strengths

Cluster headaches is episodic in 80–90% of cases, with attacks occurring daily for a few weeks to a few months, followed by a gap of a few months to a few years. The chronic variety has continuous attacks for a year or longer with no symptom-free interval or a remission period that lasts for less than a month
Recent epidemiological studies indicate that the prevalence of Cluster headaches is about one person per 500. Thus a large cohort of patients will help ensure any new entrant make substantial gains

Cluster Headaches Market Unmet Needs

Lack of Effective Treatment
Challenges in Diagnosis
Unknown Mechanism

Scope of the Cluster Headaches Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cluster Headaches Companies: Lundbeck Seattle BioPharmaceutical, Ceruvia Lifesciences, Zosano Pharma Corporation, Biohit Oyj, CCH Pharmaceuticals, Eli Lilly and Company, Winston Laboratories, and others
Key Cluster Headaches Therapies: EMGALITY (Galcanezumab-gnlm), Eptinezumab, NYPRG-101 (BOL-148), C213 Microneedle System, Acetium, Ketamine, Galcanezumab, Civamide (Zucapsaicin), and others
Cluster Headaches Therapeutic Assessment: Cluster Headaches current marketed and Cluster Headaches emerging therapies
Cluster Headaches Market Dynamics: Cluster Headaches market drivers and Cluster Headaches market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cluster Headaches Unmet Needs, KOL’s views, Analyst’s views, Cluster Headaches Market Access and Reimbursement

Discover more about therapies set to grab major Cluster Headaches market share @ Cluster Headaches Treatment Market

Table of Contents

1. Cluster Headaches Market Report Introduction

2. Executive Summary for Cluster Headaches

3. SWOT analysis of Cluster Headaches

4. Cluster Headaches Patient Share (%) Overview at a Glance

5. Cluster Headaches Market Overview at a Glance

6. Cluster Headaches Disease Background and Overview

7. Cluster Headaches Epidemiology and Patient Population

8. Country-Specific Patient Population of Cluster Headaches

9. Cluster Headaches Current Treatment and Medical Practices

10. Cluster Headaches Unmet Needs

11. Cluster Headaches Emerging Therapies

12. Cluster Headaches Market Outlook

13. Country-Wise Cluster Headaches Market Analysis (2020–2034)

14. Cluster Headaches Market Access and Reimbursement of Therapies

15. Cluster Headaches Market Drivers

16. Cluster Headaches Market Barriers

17. Cluster Headaches Appendix

18. Cluster Headaches Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cluster Headaches Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer, Sun Pharma, Teva Pharma

Across Borders and Boundaries: A Thousand Flying Things by Kathryn Brown Ramsperger Chronicles a Female Humanitarian’s Life-Altering Journey Through War-Torn Sudan and Kenya

Set against the backdrop of war-torn Africa, Kathryn Brown Ramsperger’s A Thousand Flying Things is a compelling work of multicultural fiction that weaves love, sacrifice, and self-discovery into a story that challenges perspectives on humanity, home, and healing.

Kathryn Brown Ramsperger is an award-winning novelist, journalist, and creativity expert whose work delves into multicultural relationships, social justice, immigration, and global humanitarian issues. Her novels—Moments On The Edge, The Shores of Our Souls, and A Thousand Flying Things—have earned recognition from Faulkner-Wisdom, Foreword Indies, the Sarton Awards, the Washington, DC Public Libraries, and the Pulpwood Queen’s International Books of the Year.

A storyteller rooted in Southern tradition, Kathryn’s writing is enriched by her experiences reporting and living in Africa, Europe, and the Middle East. She has contributed to notable outlets such as National Geographic, Kiplinger, and The MacGuffin, and has worked as a humanitarian reporter for the International Red Cross and Red Crescent.

As the creator of Step Into Your Story!™, Kathryn empowers creatives to find clarity and get unstuck to achieve their dreams. When not writing, Kathryn loves to sing, dance, and travel. A nature lover, her favorite animal is feline, her favorite flower, the snapdragon, and her favorite cuisine, French.

This one-on-one interview shares Kathryn’s background and experience writing A Thousand Flying Things.

Tell us about A Thousand Flying Things.

She’s brave and tenacious. She won’t be stopped by country borders, political boundaries, or illness. But decisions of the heart may just bring her to her knees.

American humanitarian Dianna Calloway is educating children in the thick of war-ravaged 1990s Southern Sudan. Hampered by disease, a corrupt government, and a fierce tribal leader who is harboring a mysterious young boy, Khalil, whom she believes he’s grooming to be a child soldier, Dianna’s resolve endures. But her passion to help others is only complicated by the chance meeting with her long-lost love, Qasim. Dianna and Qasim couldn’t be more different. He’s a worldly Lebanese Muslim in his 40s, from a political family, and she’s a 30-something white Christian American. Faced with the choice to protect Khalil or reconnect with the man she still holds dear, Dianna must make the most difficult decision of her life. Or must she? For nothing is as it seems.

Sweeping across continents and cultures, A Thousand Flying Things, informed by my own work as a humanitarian journalist, questions long-held assumptions about helping a vulnerable world and perspectives about love, family, home, and the wisdom of the young.

What inspired you to write A Thousand Flying Things?

I was inspired to give readers a peek behind the curtain into humanitarian work in a war-torn country—a world I know intimately. Travel profoundly transformed my life and worldview, and I wanted to encourage others to step outside their comfort zones.

Humanitarians may be heroes, but they also have feelings. At its core, A Thousand Flying Things is about the power of unconditional love to triumph over conflict. Through empathy and listening to one another’s stories, we can foster understanding and connection. My goal was to craft not just a compelling adventure, but also a story with heart—one that leaves readers feeling inspired and hopeful.

How did your background and experience influence your writing?

My fifth-grade teacher’s praise for my weekly essays sparked my lifelong passion for storytelling. By 21, after earning the equivalent of a BFA in creative writing and winning my university’s annual Fiction Award, I knew I wanted to write novels.

My career as a journalist has been instrumental in shaping my stories. Writing for National Geographic, Kiplinger, and scores of other magazines, as well as spending 25 years as a humanitarian reporter with the International Red Cross and Red Crescent, exposed me to a world of diverse perspectives. Living and working in Africa, Europe, and the Middle East, alongside people from 167 different nationalities, enriched my understanding of humanity, which I bring to every page.

My first novel, The Shores of Our Souls, was inspired by a transformative relationship with a former romantic partner from Lebanon, whose story continues in A Thousand Flying Things. It taught me that you don’t have to stay in a relationship for it to transform you and leave a lasting imprint on your heart.

I’m deeply influenced by writers all over the world and share this passion as a YouTube podcast host and multicultural book reviewer for The New York Journal of Books. My literary inspirations include Barbara Kingsolver, Ann Patchett, Marita Golden, Jodi Picoult, Annie Dillard, Ahdaf Soueif, and Salman Rushdie. I’ve also read every book I could find from Charles Dickens, George Eliot, Eudora Welty, EM Forster, John Steinbeck, May Sarton, and Alice Walker. These voices continue to shape my writing and my life.

What is one message you would like readers to remember?

To truly help the world, we must first look within. Love is the most powerful force we possess—a force to understand, heal, and experience true happiness and fulfillment.

Unconditional love, the kind that listens and seeks to understand others’ perspectives, is transformative. It has the power to bridge divides, conquer conflict, and transcend even death. It connects us, reminding us that we are One Humanity. It takes us from “Our Story” to “Humanity’s Greater Story.”

I don’t believe this dream is too idealistic. Whether it’s the little boy gazing at the stars in Serbia, the little girl looking up at the sky in Somalia, or the parent navigating rush hour traffic in an Illinois city, we all long for the same things: love, peace, and happiness in a calmer world. It’s a shared dream that begins with empathy and grows through connection.

Purchasing the Book

A Thousand Flying Things has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Kirkus Reviews writes, “Ramsperger’s portrayal of the ravages of South Sudan is heartbreakingly vivid…a quietly meditative and insightful novel.” Midwest Book Review writes, “Highly recommended for libraries and readers seeking evocative works that will also fuel powerful book club discussions.”

The book is available for sale on Amazon, Barnes & Noble, Bookshop.org, and other online and local indie bookstores. Readers are encouraged to purchase their copy today:

https://www.amazon.com/Thousand-Flying-Things-Bridge-Between-ebook/dp/B0DHPYF87Y/

To connect with Kathryn and learn more about her work, visit: https://kathrynbrownramsperger.com. You can also find her on Facebook, Instagram and TikTok.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Across Borders and Boundaries: A Thousand Flying Things by Kathryn Brown Ramsperger Chronicles a Female Humanitarian’s Life-Altering Journey Through War-Torn Sudan and Kenya

Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire

The Key Status Epilepticus Companies in the market include – Marinus Pharmaceuticals, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire, and others.

DelveInsight’s “Status Epilepticus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Status Epilepticus, historical and forecasted epidemiology as well as the Status Epilepticus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Status Epilepticus, offering comprehensive insights into the Status Epilepticus revenue trends, prevalence, and treatment landscape. The report delves into key Status Epilepticus statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Status Epilepticus therapies. Additionally, we cover the landscape of Status Epilepticus clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Status Epilepticus treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Status Epilepticus space.

To Know in detail about the Status Epilepticus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Status Epilepticus Market Forecast

Some of the key facts of the Status Epilepticus Market Report:

The Status Epilepticus market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In October 2024, Marinus Pharmaceuticals announced findings from the pivotal Phase III RAISE trial evaluating intravenous (IV) ganaxolone for refractory status epilepticus (RSE). The trial successfully met one of its two co-primary endpoints, demonstrating a notable impact on seizure cessation in RSE patients.
Key Status Epilepticus Companies: Marinus Pharmaceuticals, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire, and others
Key Status Epilepticus Therapies: Ganaxolone, Lorazepam, Staccato alprazolam, IV Ganaxolone active, SAGE-547, SHP615, and othes.
Research by Manuel Garcia-Ruiz et al. (2024) in Spain indicated that 23–48% of status epilepticus patients progress to refractory status epilepticus (RSE), while 22% develop super-refractory status epilepticus (SRSE). Both conditions were linked to high morbidity and mortality rates.
The Status Epilepticus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Status Epilepticus pipeline products will significantly revolutionize the Status Epilepticus market dynamics.
A study by Mevius and Joeres (2023) found that the incidence of status epilepticus in Germany was 25.5 cases per 100,000 individuals. The occurrence was slightly higher in males at 25.69 per 100,000, compared to 25.39 per 100,000 in females.
According to research by Lu and Faure (2020), the annual incidence of status epilepticus in the U.S. ranges between 18.3 and 41 cases per 100,000 individuals. This figure is expected to increase at a notable compound annual growth rate (CAGR) over the forecast period from 2024 to 2034.

Status Epilepticus Overview

Status Epilepticus is a serious and life-threatening neurological condition where a seizure lasts longer than 5 minutes or multiple seizures occur without full recovery between them. It requires immediate medical intervention to prevent brain damage, respiratory failure, or death.

It can be triggered by epilepsy, stroke, infections, head injuries, or medication withdrawal. Treatment involves intravenous antiepileptic drugs like benzodiazepines (lorazepam, diazepam) and supportive care to stabilize the patient. Prompt treatment is crucial to prevent long-term complications.

Get a Free sample for the Status Epilepticus Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/status-epilepticus-market

Status Epilepticus Epidemiology

Status Epilepticus Epidemiology Segmentation:

The Status Epilepticus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Status Epilepticus
Prevalent Cases of Status Epilepticus by severity
Gender-specific Prevalence of Status Epilepticus
Diagnosed Cases of Episodic and Chronic Status Epilepticus

Download the report to understand which factors are driving Status Epilepticus epidemiology trends @ Status Epilepticus Epidemiology Forecast

Status Epilepticus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Status Epilepticus market or expected to get launched during the study period. The analysis covers Status Epilepticus market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Status Epilepticus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Status Epilepticus Therapies and Key Companies

Ganaxolone: Marinus Pharmaceuticals
Lorazepam: Pfizer
Staccato alprazolam: UCB Biopharma SRL
IV Ganaxolone active: Marinus Pharmaceuticals
SAGE-547: Sage Therapeutics
SHP615: Shire

Discover more about therapies set to grab major Status Epilepticus market share @ Status Epilepticus Treatment Landscape

Status Epilepticus Market Drivers

Rising Prevalence of Epilepsy & Neurological Disorders
Advancements in Treatment Options
Growing Awareness & Early Diagnosis
Government & Private Sector Initiatives
Technological Innovations in Drug Delivery

Status Epilepticus Market Barriers

High Treatment Costs
Adverse Effects of Antiepileptic Drugs
Delayed Diagnosis & Treatment
Regulatory Challenges & Drug Approval Delays

Scope of the Status Epilepticus Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Status Epilepticus Companies: Marinus Pharmaceuticals, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire, and others
Key Status Epilepticus Therapies: Ganaxolone, Lorazepam, Staccato alprazolam, IV Ganaxolone active, SAGE-547, SHP615, and others
Status Epilepticus Therapeutic Assessment: Status Epilepticus current marketed and Status Epilepticus emerging therapies
Status Epilepticus Market Dynamics: Status Epilepticus market drivers and Status Epilepticus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Status Epilepticus Unmet Needs, KOL’s views, Analyst’s views, Status Epilepticus Market Access and Reimbursement

To know more about Status Epilepticus companies working in the treatment market, visit @ Status Epilepticus Clinical Trials and Therapeutic Assessment

Table of Contents

1. Status Epilepticus Market Report Introduction

2. Executive Summary for Status Epilepticus

3. SWOT analysis of Status Epilepticus

4. Status Epilepticus Patient Share (%) Overview at a Glance

5. Status Epilepticus Market Overview at a Glance

6. Status Epilepticus Disease Background and Overview

7. Status Epilepticus Epidemiology and Patient Population

8. Country-Specific Patient Population of Status Epilepticus

9. Status Epilepticus Current Treatment and Medical Practices

10. Status Epilepticus Unmet Needs

11. Status Epilepticus Emerging Therapies

12. Status Epilepticus Market Outlook

13. Country-Wise Status Epilepticus Market Analysis (2019–2032)

14. Status Epilepticus Market Access and Reimbursement of Therapies

15. Status Epilepticus Market Drivers

16. Status Epilepticus Market Barriers

17. Status Epilepticus Appendix

18. Status Epilepticus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire

Breast Cancer Market to Witness Upsurge in Growth by 2032, According to DelveInsight

Leading Breast Cancer companies in the market include – Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, and Daiichi Sankyo, among others.

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, and Daiichi Sankyo, among others.

DelveInsight’s latest report, “Breast Cancer – Market Insight, Epidemiology and Market Forecast – 2032” combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the breast cancer market in the 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase significantly for the forecasted period. The US accounted for the largest market share among the 7MM. Factors such as the rising incidence of Multiple Myeloma, the growing aging population, and the increasing adoption of novel therapies like CAR-T cell therapies and bispecific antibodies are contributing to this expansion.

Download the Breast Cancer market report to understand which factors are driving the Breast Cancer therapeutic market @ Breast Cancer Market Trends

The report also offers an in-depth epidemiological analysis and forecasts up to 2032, segmented by total incident cases of breast cancer, incident cases of breast cancer by menopausal status, stage-specific incident cases of breast cancer, subtype-specific incident cases of breast cancer,subtype-specific incident cases of breast cancer by mutation, and treatment eligible pool for early and metastatic breast cancer. According to research conducted by DelveInsight, breast cancer is the most common cancer in women in the United States other than skin cancer, with about 30% of all new female cancers each year. Additionally, the breast cancer subtype HR+/HER2- is the most common subtype in the US with approximately 140K cases.

The Delveinsight report also discusses current diagnosis and treatment strategies for Breast cancer. The stage of breast cancer is an essential factor in making treatment decisions. Most women with breast cancer in Stages I, II, or III are treated with surgery, often followed by radiation therapy. Some of the drugs approved for breast cancer treatment include IBRANCE (Pfizer), ITOVEBI (Roche), DATROWAY (AstraZeneca and Daiichi Sankyo), and LYNPARZA (AstraZeneca), among others. LYNPARZA is the first and only approved medicine targeting BRCA mutations in early breast cancer.

Discover evolving trends in the Breast Cancer treatment landscape @ Breast Cancer Therapeutics Market

There are several therapies, such as Camizestrant (AstraZeneca) and Lasofoxifene (Sermonix Pharmaceuticals), among others are being investigated across multiple clinical phases for breast cancer treatment.

Recent developments, including the FDA approval of DATROWAY (AstraZeneca and Daiichi Sankyo) in January 2025 and ITOVEBI (Roche) in October 2024, emphasize the momentum in the breast cancer therapeutic landscape.

Recent advancements in diagnostics, such as the FDA’s Breakthrough Device Designation for the HyperVIEW X-Ray system (developed by Lumitron Technologies) in February 2025 and for FoundationOne Liquid CDx (Foundation Medicine) in October 2024 to serve as a companion diagnostic for the cancer therapy ITOVEBI (Roche), are facilitating early breast cancer detection. As a result, early diagnoses are increasing, contributing to a higher incidence of breast cancer cases and ultimately driving market growth.

Unlock which Breast Cancer drug is expected to capture the largest market share in 7MM by 2032. Visit the Breast Cancer Market Insights

These advancements indicate a positive trajectory for the breast cancer market, with increasing therapeutic options potentially improving patient outcomes and market growth in the coming decade.

Table of Contents

1.	Key Insights
2.	Report Introduction
3.	Executive Summary of Breast Cancer
4.	Key Events
5.	SWOT Analysis
6.	Breast Cancer Market Overview at a Glance in the 7MM
7.	Breast Cancer Background and Overview
8.	Breast Cancer Treatment
9.	Breast Cancer Epidemiology and Patient Population of 7MM
10.	Breast Cancer Patient Journey
11.	Breast Cancer Marketed Therapies
12.	Breast Cancer Emerging Therapies
13.	Breast Cancer: 7MM Market Analysis
14.	Breast Cancer Unmet Needs
15.	Market Access and Reimbursement
16.	Appendix
17.	DelveInsight Capabilities
18.	Disclaimer
19.	About DelveInsight

Related Reports

Breast Cancer Pipeline Insight

Breast Cancer Pipeline Insight provides comprehensive insights about the Breast Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Breast Cancer companies, including Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co. Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc. and Horizon Therapeutics among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Cancer Market to Witness Upsurge in Growth by 2032, According to DelveInsight

Top Real Estate Listing Agent in Scottsdale, AZ Launches Innovative Website Empowering Sellers with Multiple Selling Strategies

SCOTTSDALE, AZ – Those Callaways real estate agency run by one of the top top real estate agents in Scottsdale, AZ has launched a groundbreaking new website designed to revolutionize how homeowners approach selling their properties. The platform, WhenYouWantaSOLDSign.com, offers users the ability to select from multiple selling strategies tailored to their specific needs and circumstances.

The innovative website stands out in the competitive real estate market by giving sellers unprecedented control over their home selling process.

“We created this platform because we believe sellers deserve choices,” said Joseph Callaway, real estate agent in Scottsdale, AZ. “Every property and seller has unique needs, and our new website empowers homeowners to select the path that works best for their specific situation without being forced into a one-size-fits-all approach.”

The website highlights several distinct selling approaches, including options for those seeking quick cash offers with no showings or commissions. Homeowners looking for maximum return can choose strategies that position their properties for top dollar through professional staging and comprehensive marketing. The platform also offers specialized solutions for those dealing with divorce, estate sales, or pre-foreclosure circumstances.

One standout feature is the transparency regarding commissions, which vary based on the chosen strategy. The site explains that all commissions are negotiable, with some options starting as low as 0.5% for simple transactions between friends and family members. For sellers wanting a more hands-on approach, the “Flip It Myself” option connects homeowners with Realtor agents in Scottsdale, AZ who provide resources and contractor recommendations.

“What makes this website truly different is the ‘Power of No’ concept,” added Callaway. “We emphasize that sellers always maintain control throughout the process. Even with multiple offers above asking price, homeowners have the absolute right to decline any offer with no obligation whatsoever.”

For homeowners considering selling their property in today’s dynamic market, Those Callaways real estate listing agents in Scottsdale, AZ invite them to explore all available options by visiting WhenYouWantaSOLDSign.com or contacting them directly through their main website at https://www.thosecallaways.com/ to discover which selling strategy might be most advantageous for their unique situation.

Media Contact
Company Name: Those Callaways Real Estate
Contact Person: Joseph Callaway
Email: Send Email
Phone: +1 480 596 5751
Address:7217 E Shea Blvd.
City: Scottsdale
State: Arizona 85260
Country: United States
Website: https://www.thosecallaways.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Listing Agent in Scottsdale, AZ Launches Innovative Website Empowering Sellers with Multiple Selling Strategies

Top Real Estate Agent in Cape Coral, FL, Recognized Among Top 10% Nationally with RE/MAX Platinum Award

For the fifth time in the last six years, Bob Ashworth, a top real estate agent in Cape Coral, FL, has been honored with the prestigious RE/MAX Platinum Club award for 2024. This recognition places Bob among the top 10% of real estate professionals nationwide, showcasing his dedication and consistent performance in the real estate industry.

“Bob’s dedication to our clients and his exceptional market knowledge have been key to his continued success,” said Jenn Spears, the leading Realtor at RE/MAX Realty Team. “His ability to consistently meet and exceed client expectations is what truly sets him apart. We are proud to be part of a team that delivers such high standards of service year after year.”

As a top Realtor in Cape Coral, FL, Bob’s client-focused approach has earned him the trust of many homebuyers and sellers in Southwest Florida. He and his team are known for their meticulous attention to detail, ensuring that every client receives personalized service throughout the entire real estate process. Their commitment to prompt communication—whether by phone, text, or email—ensures clients’ needs are always met.

Bob’s expertise as a real estate listing agent in Cape Coral, FL, goes beyond sales; it’s about educating clients on market trends and providing clear, honest information to help them make informed decisions. With a background in precision manufacturing, Bob applies his analytical skills to real estate transactions, using a strategic approach to secure the best outcomes for his clients.

As a real estate selling agent in Cape Coral, FL, Bob’s approach to marketing homes and negotiating on behalf of his clients has consistently resulted in top-dollar sales. His knowledge of the local market and proven track record make him a go-to agent for both buyers and sellers in Cape Coral and the surrounding areas.

To learn more about Bob Ashworth’s services and how he can help you achieve your real estate goals, visit http://bobashworthrealty.com/. Contact Bob and Jenn today for expert guidance and exceptional service in Southwest Florida’s real estate market.

Media Contact
Company Name: Re/Max Realty Team: Bob Ashworth PA & Jenn Spears Real Estate Agent in Cape Coral FL
Contact Person: Bob Ashworth
Email: Send Email
Phone: +1 239-898-2716
Address:2326 Del Prado Blvd S
City: Cape Coral
State: Florida
Country: United States
Website: bobashworthrealty.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Cape Coral, FL, Recognized Among Top 10% Nationally with RE/MAX Platinum Award

Top Real Estate Selling Agent in Boca Raton, FL Achieves International Recognition with Innovative Marketing Strategies

Boca Raton, FL – Matan Morag, a highly regarded real estate listing agent in Boca Raton, FL, has gained international recognition for his cutting-edge marketing techniques that consistently deliver exceptional results for luxury home sellers. Specializing in the ultra-luxury South Florida market for over a decade, Matan has built a reputation for successfully marketing and selling high-end estates, waterfront properties, and exclusive country club homes. His innovative approach ensures that every property he represents receives maximum exposure and attracts the right buyers.

Matan’s background in finance and investment analysis sets him apart in the luxury real estate space. With degrees from the London School of Economics and the University of Miami, he applies a data-driven approach to pricing and negotiation. “Selling luxury real estate requires more than just traditional marketing—it demands an analytical strategy tailored to the ever-changing market,” says Matan Morag, top Realtor agent in Boca Raton, FL. “I use my financial expertise to structure deals that benefit my clients, ensuring they achieve top-dollar results.”

His commitment to excellence is reflected in his ability to reach a global audience. As a multilingual professional fluent in Hebrew and Spanish, among other languages, Matan effectively connects with international buyers looking to invest in South Florida’s prestigious real estate market. As a leading Boca Raton, FL Realtor, he combines high-impact digital marketing, targeted advertising, and personalized service to create a seamless experience for both local and international clients.

Matan’s dedication to his clients and his aggressive marketing approach have earned him multiple International & Global Diamond Awards year after year. His ability to drive success in one of the nation’s most competitive luxury real estate markets makes him a top choice for sellers seeking results. As a trusted real estate selling agent in Boca Raton, FL, he offers a full-service experience, from home staging and market analysis to contract negotiation and closing.

For luxury homeowners looking to maximize their property’s exposure and sale price, Matan Morag provides the expertise and proven marketing strategies needed to achieve outstanding results. “My goal is to give sellers an edge in the market by using the most advanced marketing techniques available,” he shares.

Visit https://matanmoragpa.com/ to learn more about his services or to schedule a consultation today.

Media Contact
Company Name: MATAN MORAG, P.A. AT REGENCY REALTY SERVICES
Contact Person: Matan Morag
Email: Send Email
Phone: +1 561-706-0095
Address:861 Yamato Road Ste 5
City: Boca Raton
State: Florida 33431
Country: United States
Website: https://matanmoragpa.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Selling Agent in Boca Raton, FL Achieves International Recognition with Innovative Marketing Strategies

Top Real Estate Selling Agent in Capitola, CA, Focuses on Maximizing Property Value in Today’s Competitive Market

As a real estate listing agent in Capitola, CA, Alex Johnson is dedicated to helping homeowners maximize the value of their properties in today’s fast-paced and competitive real estate market. With years of experience in the Santa Cruz area, Alex leverages his deep knowledge of local market trends and effective marketing strategies to help sellers achieve top-dollar sales.

“The key to a successful home sale is ensuring that the property stands out and is priced correctly,” says Alex Johnson. “By focusing on enhancing a property’s appeal and utilizing the latest marketing tools, I make sure my clients get the best possible value for their homes.”

As a seasoned real estate agent in Capitola, CA, Alex works closely with sellers to create a customized plan that highlights the best features of their homes. From professional staging to expert pricing strategies, Alex provides comprehensive services designed to attract serious buyers and ensure a smooth transaction. His local knowledge and access to real-time market data allow him to price properties competitively, helping sellers secure the best offers.

In addition to his expertise as a Realtor agent in Capitola, CA, Alex partners with a network of trusted local contractors and service providers to assist with any repairs or improvements that may enhance a home’s value. By offering full-service support throughout the selling process, Alex ensures that his clients are well-prepared to present their homes in the best light.

For homeowners in Capitola and the surrounding areas looking to sell, Alex’s dedication to maximizing property value and his extensive knowledge of the market make him the ideal real estate selling agent in Capitola, CA. Whether it’s a luxury beachfront property or a cozy home in the redwoods, Alex’s approach delivers exceptional results.

To learn more about how Alex can help you sell your home for top dollar, visit https://www.santacruzluxhomes.com/. Contact Alex Johnson today for expert guidance and support in achieving your real estate goals.

Media Contact
Company Name: Alex Johnson, David Lyng Real Estate | Real Estate Agent in Capitola CA & Santa Cruz
Contact Person: Alex Johnson
Email: Send Email
Phone: +1 (831) 234-5754
Address:301 Capitola Ave
City: Capitola
State: California 95010
Country: United States
Website: https://www.santacruzluxhomes.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Selling Agent in Capitola, CA, Focuses on Maximizing Property Value in Today’s Competitive Market